The BCAL Diagnostics Team
Get to Know Us
Chairman & Co-Founder
Trained as a Registered Nurse in the UK, on arrival in Australia she became a Director of Nursing and Chief Executive Officer of two private hospitals. Following this she established an Australian and International consulting business which was sold to Healthsouth a large US Healthcare company. After this she became the Co-founder of Vision Group an Opthalmic Doctor equity consolidation model which was successfully listed on the ASX. Jayne joined a number of private Healthcare Boards involved with specialist consolidation including Cardiology, Orthopaedics, and Women’s Health she continued to work with Private Equity firms on local and International Healthcare transactions. Jayne, together with Ron Phillips was a co-owner of Sydney Breast Clinic and a co-founder of BCAL Diagnostics. Current Board positions are Critical Group – Heatley’s Industrial Supplies, The Woolcock Research Institute, and The Hareda Foundation established to invest in Women’s Health Initiatives.
The Hon Ron Philips (AO)
Director & Co-Founder
Following 15 years in the NSW Parliament which included serving as Minister for Health and Deputy Leader of the Opposition, Ron developed a successful consulting business in the Health and Aged Care Industry.
His business interests included co-owner and Managing Director of Sydney Breast Clinic which he sold to Healthscope. He currently serves as Chair of the Sydney Local Health District and as Director on Westmead IVF.
Dr Amani Batarseh, PhD
Chief Scientific Officer
Dr Amani Batarseh is the company’s Chief Scientist. She graduated magna cum laude from La Roche College in Pennsylvania where she had a Pacem in Terris scholarship for academic excellence. Later, she received a fellowship to purse her PhD at Georgetown University, Washington, DC in Biochemistry and Molecular & Cellular Biology. Amani completed post doctoral studies at Harvard University, McGill University and Wollongong University. During her time in Canada, Amani managed and established two mass spectrometry laboratories being at the Research Institute of McGill University Hospital and The Glen Hospital in Montreal, respectively. Her versatile profile of expertise combines molecular biology with lipidomics and mass spectrometry to answer biological questions.
Kerry is the company’s Research Assistant. Kerry recently graduated with First Class Honours from the University of Sydney. He presented his Honours project at the 2019 ASCEPT-PAGANs conference in Queenstown NZ.
Kerry as a diverse range of professional interests including health, carcinogenesis, machine learning, programming and metabolomics.
Jonathan is a globally experienced independent director with over 30 years commercial, corporate, governance and legal and transactional expertise.
Jonathan is currently non-executive independent chairman of ASX listed Global Value Fund Ltd Future Generation Investment Company Ltd , Antipodes Global Investment Company Ltd and Plato Income Maximizer Limited . He is a non-executive director of ASX listed Kore Potash Limited and holds private company directorships in the commercial and not-for-profit sectors.
Jonathan was a principal of Sydney, Australia based structured finance group Meridian International Capital Limited for over 20 years, Prior to that, Jonathan was a partner with law firm Herbert Smith Freehills. Jonathan currently has a New South Wales Law Society Practicing Certificate and is a Fellow of the Australian Institute of Company Directors.
Experience across Consumer Healthcare, FMCG and Startups specialising in brand management and digital marketing. Rebecca has worked on some of Australia's market leading Consumer Healthcare brands such as Panadol, Voltaren, Centrum and Sensodyne to drive brand growth and sales.
Corporate Finance Advisor
Charlie has 30 years of global capital raising and mergers and acquisitions experience. After a career holding senior positions at Baring Brothers, Macquarie Bank, Investec and EY, working in Australia, SE Asia, South Africa and the UK, he now runs an independent advisory boutique. Charlie has an M&A in Economics from Cambridge University, is a Fellow of the Institute of Chartered Accountants in England and Wales and is a Graduate of the Australian Institute of Company Directors.
Mr Paul Cohen B.AppSc (Biomedical)
Clinical Trial Coordinator
Paul has greater than 26 years’ experience in the diagnostics, biotechnology, medical device, and bio-pharmaceutical industry. His expertise spans clinical research, regulatory affairs, pharmacovigilance, training, quality management and process re-engineering for large pharmaceutical companies, biotech and medical device/IVD start-up ventures.
His clinical research therapeutic area expertise includes medical devices-CLASS I-III, IVDs, vaccines and biologicals, anti-infectives, transplantation, antidepressants, rheumatology, oncology, diabetes, respiratory and orthopaedics.
market/PV pre and post market obligations and risk management. He holds an ARCS Certified Fellowship in Clinical Research and is a member of ARCS, AIMS, ASM, RAPS and a Subject Matter Expert for the World Medical Device Organisation.
Dr Kim Ekroos, PhD
Lipidomics and Mass Spectrometry
Kim Ekroos is the founder and CEO of Lipidomics Consulting Ltd., a consulting business providing unique services for customers globally in the field of Lipidomics. He received his Ph.D. degree in biology from the Technical University in Dresden, Germany, in 2003. His expertise includes high-throughput technologies for the precise assessment of lipidomes enabled by advanced mass spectrometry, automation, and software tools towards discovery of biological architectures and of diagnostic biomarkers for clinical purpose.
Kim is a globally experienced independent consultant for Lipidomics with over 20 years academics, healthcare and industry expertise. He has a number of patents for biomarker discovery, numerous peer-reviewed publications and an editor of a widely read Lipidomics book. He is the current president of the newly founded International Lipidomics Society (ILS) to which the Lipidomics Standards.
A/Prof Craig Gedye
BSc(Hons), MBChB, FRACP, PhD
Biospecimen and Clinical Research
Craig Gedye is a medical oncologist and cancer researcher. He works for people with melanoma, brain, prostate, bladder and kidney cancers at the Calvary Mater Newcastle and is the Clinical Research Director at the NSW Health Statewide Biobank.
His research in the School of Medicine and Public Health at the University of Newcastle/Hunter Medical Research Institute focuses on complexity and heterogeneity in cancer – "why are cancers different between different people; why are cancers cells different to each other; what does this mean for each person’s treatment?"
Craig is leading several national cancer clinical trials for the ANZUP and COGNO trials groups, and is a member of the Mark Hughes Scientific Advisory Committee, HNEHLD Clinical Trials Ethics Subcommittee and ANZUP Cancer. He has been awarded numerous scholarships, fellowships, grants, investigator-initiated clinical trials, publications, conference presentations and prizes.